AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Teva Pharmaceutical Industries Ltd.

Director's Dealing Dec 5, 2025

7082_rns_2025-12-04_25c0cfa9-cfb6-4f94-9f63-20d1a392bf78.pdf

Director's Dealing

Open in Viewer

Opens in native device viewer

FORM 4 OMB APPROVAL
Check this box if no longer subject to Section 16.
Form 4 or Form 5 obligations may continue. See
Instruction 1(b).
Check this box to indicate that a transaction was
made pursuant to a contract, instruction or written
plan for the purchase or sale of equity securities of
the issuer that is intended to satisfy the affirmative
defense conditions of Rule 10b5-1(c). See
Instruction 10.
(Print or Type Responses)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB Number:
Estimated average burden hours per
response
3235-0287
0.5
1. Name and Address of Reporting Person *
Chen Lichtenstein
2. Issuer Name and Ticker or Trading Symbol
Teva Pharmaceutical Industries Limited [ TEVA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director
10% Owner
Officer (give title below)
Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
Form filed by More than One Reporting Person
(Last)
(First)
C/O Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.,
(Middle) 3. Date of Earliest Transaction (Month/Day/Year)
12/02/2025
(Street)
Tel Aviv, L3 6944020
4. If Amendment, Date Original Filed (Month/Day/Year)
(City)
(State)
(Zip)

Disposed of (D) (Instr. 3, 4 and 5)

Code V Amount (A) or (D) Price

Following Reported Transaction(s)

Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

of Indirect Beneficial Ownership (Instr. 4)

(Instr. 3 and 4)

Date (Month /Day/Year)

Execution Date, if any (Month/Day /Year)

Code (Instr. 8)

Ordinary Shares (1) 12/02/2025 M 4,804 A (2) 4,804 D

(Instr. 3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative
Security
(Instr. 3)
2. Conversion
or Exercise
Price of
Derivative
Security
3. Transaction
Date (Month
/Day/Year)
3A. Deemed
Execution
Date, if any
(Month/Day
/Year)
4. Transaction
Code
(Instr. 8)
5. Number of
Derivative Securities
Acquired (A) or
Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration
Date
(Month/Day/Year)
7. Title and Amount of
Underlying Securities
(Instr. 3 and 4)
8. Price of
Derivative
Security
(Instr. 5)
9. Number
of
Derivative
Securities
Beneficially
10.
Ownership
Form of
Derivative
Security:
11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or
Number of
Shares
Owned
Following
Reported
Transaction
(s)
(Instr. 4)
Direct (D)
or Indirect
(I)
(Instr. 4)
Restricted Share
Units
(2) 12/02/2025 M 4,804 (3) (3) Ordinary
Shares (1)
4,804 \$ 0 0 D

Explanation of Responses:

  • 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • 2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • 3. Restricted share units were granted on December 2, 2024 and vested on December 2, 2025.

/s/ Dov Bergwerk as attorney-in-fact for Chen Lichtenstein 12/04/2025 Signature of Reporting Person ** Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Talk to a Data Expert

Have a question? We'll get back to you promptly.